A Mother’s Quest to Help Her Son Hear
Clinical Trials, Ear, Ear Nose Throat, Health, Hearing, UNC Children's, UNC Stories
Category: Clinical Trials
Cancer Clinical Trials Don’t Have to Be a Last Resort
Learn how you can play a more active role in your treatment and help other patients, too.
‘Conversations with Innovators:’ UNC hematologist on promising drug...
Kenneth Ataga, MD, director of the UNC Comprehensive Sickle Cell Program, was featured in a video by the American Society of Hematology in which he discussed the favorable results of a yearlong clinical trial studying crizanlizumab as a therapy to prevent and treat painful crisis events in patients with sickle cell disease.
The purist: Chapel Hill man shares journey of HIV clinical trials a...
Robert Hill has been living with HIV for 22 years. Five years ago, he enrolled in a study at the UNC School of Medicine, which was part of Dr. David Margolis’ ‘kick and kill’ strategy for eradicating HIV by flushing it out of hiding with a drug called Vorinostat and killing it with either a vaccine
‘To seek a true cure’: UNC researchers pioneer HIV research w...
In honor of World AIDS Day on Dec. 1, we take a look at the trailblazing ‘kick and kill’ method of attacking HIV to cure patients. UNC researchers have been working with GlaxoSmithKline on parallel studies at the UNC Cure Center for 18 months to advance this new method of combating the global epidemic of HIV.
UNC a lead site in clinical trial of three hepatitis C medications
Dr. Michael Fried, director of the UNC Liver Center, is a co-principal investigator of the PRIORITIZE Study.
UNC enrolling patients in Momentum 3 Clinical Trial
UNC is one of 60 medical centers nationwide chosen to participate in the MOMENTUM 3 Clinical Trial to evaluate the effectiveness and safety of the Thoratec® HeartMate 3™ Left Ventricular Assist Device (LVAD). This multi-center study will compare the HeartMate 3 LVAD to the HeartMate II® LVAD in advanced stage heart failure patients.
New study questions clinical trial data for kidney cancer drugs
Participants in stage IV renal cell cancer drug trials are younger and healthier than many patients who don’t qualify for research studies.
Clinical Research Forum selects genomic analysis as top 10 research...
A cancer genomics study led by UNC Lineberger researchers and other scientists involved in The Cancer Genome Atlas (TCGA) project, a National Cancer Institute and National Human Genome Research Institute-backed effort to create a comprehensive atlas of the genetic changes in cancer, was selected as one of the top 10 clinical research achievements of the year.
New UNC Lineberger faculty recruited to launch T-cell cancer therap...
Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials that will test an experimental treatment in which patients’ own immune cells are genetically engineered to fight their cancer.
Two UNC doctors participating in Ebola clinical trial
William A. Fischer II and David Wohl are taking part in a clinical trial at ELWA Hospital in Monrovia, Liberia, in which plasma from survivors of Ebola virus disease is given to patients who are battling the disease.
UNC awarded $6.25 million renewal grant by NIH Rare Diseases Resear...
The University of North Carolina at Chapel Hill has been awarded a five-year, $6.25 million renewal grant to continue its work as part of the National Institutes of Health’s Rare Diseases Clinical Research Network (RDCRN).